These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35153194)

  • 1. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
    Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
    Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
    Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
    Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A.
    Tang LWT; Fu J; Koh SK; Wu G; Zhou L; Chan ECY
    Drug Metab Dispos; 2022 Jul; 50(7):931-941. PubMed ID: 35512804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
    Tang LWT; Teng JW; Koh SK; Zhou L; Go ML; Chan ECY
    Chem Res Toxicol; 2021 Jul; 34(7):1800-1813. PubMed ID: 34189909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
    Tang LWT; Verma RK; Fan H; Chan ECY
    Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
    Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
    Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
    Tang LWT; Wu G; Chan ECY
    J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
    Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
    Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
    Foo WY; Tay HY; Chan EC; Lau AJ
    Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
    Sun C; Zhao H; Li W; Jia Y; Yang Y; Peng Y; Zheng J
    Drug Metab Dispos; 2021 Oct; 49(10):892-901. PubMed ID: 34312304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperine Is a Mechanism-Based Inactivator of CYP3A.
    Cui T; Wang Q; Tian X; Zhang K; Peng Y; Zheng J
    Drug Metab Dispos; 2020 Feb; 48(2):123-134. PubMed ID: 31748224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytochrome P450 3A-mediated two-step oxidation metabolism of dimethomorph: Implications in the mechanism-based enzyme inactivation.
    Wang JY; Li JX; Ning J; Huo XK; Yu ZL; Tian Y; Zhang BJ; Wang Y; Sa D; Li YC; Lv X; Ma XC
    Sci Total Environ; 2022 May; 822():153585. PubMed ID: 35121040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
    Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
    Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
    Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
    Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
    Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
    Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.
    Wen B; Chen Y; Fitch WL
    Drug Metab Dispos; 2009 Jul; 37(7):1557-62. PubMed ID: 19364830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.
    Bauman JN; Frederick KS; Sawant A; Walsky RL; Cox LM; Obach RS; Kalgutkar AS
    Drug Metab Dispos; 2008 Jun; 36(6):1016-29. PubMed ID: 18332080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
    Kosaka M; Zhang D; Wong S; Yan Z
    Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
    Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
    Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.